title: An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.
abstract: BACKGROUND
  Epithelial ovarian cancer (EOC) is one of the most lethal gynecological cancers; the majority of EOC is the serous histotype and diagnosed at advanced stage. IL6 is the cytokine that has been found most frequently associated with carcinogenesis and progression of serous EOCs. IL6 is a growth-promoting and anti-apoptotic factor, and high plasma levels of IL6 in advanced stage EOCs correlate with poor prognosis. The objective of the present study was to identify IL6 co-regulated genes and gene network/s in EOCs.
  
  
  RESULTS
  We applied bioinformatics tools on 7 publicly available data sets containing the gene expression profiles of 1262 EOC samples. By Pearson's correlation analysis we identified, in EOCs, an IL6-correlated gene signature containing 40 genes mainly associated with proliferation. 33 of 40 genes were also significantly correlated in low malignant potential (LMP) EOCs, while 7 genes, named C5AR1, FPR1, G0S2, IL8, KLF2, MMP19, and THBD were IL6-correlated only in advanced stage EOCs. Among the 40-gene signature EGFR ligand HBEGF, genes of the EGR family members and genes encoding for negative feedback regulators of growth factor signaling were included. The results obtained by Gene Set Enrichment and Ingenuity Pathway Analyses enabled the identification, respectively, of gene sets associated with 'early growth factor response' for the 40-gene signature, and a biological network related to 'thrombosis and cardiovascular disease' for the 7-gene signature. In agreement with these results, selected genes from the identified signatures were validated in vitro by real time RT-PCR in serous EOC cell lines upon stimulation with EGF.
  
  
  CONCLUSIONS
  Serous EOCs, independently of their aggressiveness, co-regulate IL6 expression together with that of genes associated to growth factor signaling, arguing for the hypothesis that common mechanism/s driven by EGFR ligands characterize both advanced-stage and LMP EOCs. Only advanced-stage EOCs appeared to be characterized by a scenario that involves genes which are so far associated with thrombosis and cardiovascular disease, thus suggesting that this pathway is implicated in the growth and/or spread of more aggressive tumors. We have discovered novel activated signaling pathways that drive the expression of IL6 and of co-regulated genes and are possibly involved in the pathobiology of EOCs.
authors.affiliation: Unit of Molecular Therapies, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Pinciroli
authors.forename: Chiara
authors.initials: C
authors.lastname: Alberti
authors.forename: Marialuisa
authors.initials: M
authors.lastname: Sensi
authors.forename: Silvana
authors.initials: S
authors.lastname: Canevari
authors.forename: Antonella
authors.initials: A
authors.lastname: Tomassetti
mesh_terms: D000077216:Carcinoma, Ovarian Epithelial; D045744:Cell Line, Tumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D023281:Genomics; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D007375:Interleukin-1 / Q000235:genetics*; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000150:complications / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000150:complications / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D015398:Signal Transduction; D013927:Thrombosis / Q000150:complications; D059467:Transcriptome
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; D007375:Interleukin-1
references.citation: Cell Cycle. 2009 Mar 1;8(5):683-8
references.pmid: 19221481
references.citation: J Exp Med. 2009 Jul 6;206(7):1457-64
references.pmid: 19564351
references.citation: Nature. 2011 Jun 29;474(7353):609-15
references.pmid: 21720365
references.citation: Oncogene. 2004 Oct 21;23(49):8171-83
references.pmid: 15377994
references.citation: Clin Cancer Res. 2009 Apr 1;15(7):2448-55
references.pmid: 19318476
references.citation: J Cell Physiol. 2010 Aug;224(2):549-58
references.pmid: 20432456
references.citation: Nat Rev Cancer. 2011 Sep 23;11(10):719-25
references.pmid: 21941283
references.citation: Cancer Res. 2007 Jan 15;67(2):585-92
references.pmid: 17234767
references.citation: J Invest Dermatol. 2008 Mar;128(3):749-53
references.pmid: 17882266
references.citation: J Invest Dermatol. 2011 Dec;131(12):2448-57
references.pmid: 21796150
references.citation: Epidemiology. 2012 Mar;23(2):311-9
references.pmid: 22252409
references.citation: Oncogene. 2012 Sep 13;31(37):4139-49
references.pmid: 22158046
references.citation: Cancer Discov. 2012 Apr;2(4):311-9
references.pmid: 22576208
references.citation: Nat Genet. 2007 Apr;39(4):503-12
references.pmid: 17322878
references.citation: Clin Cancer Res. 2010 Dec 1;16(23):5759-69
references.pmid: 20699329
references.citation: Nature. 2006 Jan 19;439(7074):353-7
references.pmid: 16273092
references.citation: Cancer Res. 2006 Nov 15;66(22):10709-19
references.pmid: 17090524
references.citation: Am J Surg Pathol. 2010 Mar;34(3):433-43
references.pmid: 20154587
references.citation: Cancer Res. 2011 Jan 15;71(2):424-34
references.pmid: 21123455
references.citation: Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21
references.pmid: 16297528
references.citation: Nat Rev Cancer. 2009 Jun;9(6):415-28
references.pmid: 19461667
references.citation: Cancer Metastasis Rev. 2012 Jun;31(1-2):143-62
references.pmid: 22101807
references.citation: BMC Cancer. 2011 May 30;11:210
references.pmid: 21619709
references.citation: Mol Cancer Res. 2011 Dec;9(12):1658-67
references.pmid: 21976712
references.citation: Cancer Lett. 2010 Sep 1;295(1):110-23
references.pmid: 20236757
references.citation: Cancer Res. 2005 Dec 1;65(23):10794-800
references.pmid: 16322225
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24
references.pmid: 19251651
references.citation: J Biol Chem. 2010 Nov 12;285(46):35462-70
references.pmid: 20826776
references.citation: J Biol Chem. 2007 Feb 9;282(6):4045-56
references.pmid: 17142811
references.citation: Cancer Res. 2012 Jun 1;72(11):2701-4
references.pmid: 22593197
references.citation: Curr Pharm Des. 2012;18(25):3816-27
references.pmid: 22591418
references.citation: J Clin Oncol. 2007 Feb 10;25(5):517-25
references.pmid: 17290060
references.citation: Mol Cancer Res. 2008 Nov;6(11):1678-90
references.pmid: 19010816
references.citation: Cancer. 1994 Apr 1;73(7):1882-8
references.pmid: 8137215
references.citation: PLoS One. 2010 Sep 22;5(9):e12701
references.pmid: 20877637
references.citation: Clin Cancer Res. 2008 Aug 15;14(16):5198-208
references.pmid: 18698038
references.citation: PLoS One. 2010 Mar 12;5(3):e9615
references.pmid: 20300634
references.citation: J Biol Chem. 2007 Jun 1;282(22):16278-87
references.pmid: 17430890